Findings from a postmarketing observational study showed an increased risk of GBS during the 42 days following vaccination.

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Regulators say, however, the benefits of vaccination with Abrysvo and Arexvy in preventing respiratory syncytial virus ...

The FDA has required the manufacturers of the RSV Vaccines Abrysvo and Arexvy to add a new warning to their labels about the ...

The FDA is adding a warning about Guillain-Barré syndrome to the respiratory syncytial virus vaccines manufactured by GSK and ...

Barré syndrome, although it said data don’t prove a causal link and affirmed the shots’ benefit outweighs their risks.

The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning ...

The CDC recommends a single dose of any FDA-approved RSV vaccine for all adults ages 75 years and older, as well as for 60- ...

A post-marketing review by the FDA detected an increased risk of the autoimmune condition in patients inoculated with GSK’s ...

On the other hand, if the FDA rejects Annexon's filing, Annexon may have to go back and revise its RWE study or even open a ...

Rare Guillain-Barré Syndrome cases were found after ChAdOx1 vaccine in India; vigilance is urged despite vaccine’s overall safety.